Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
120 participants
INTERVENTIONAL
1999-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sensorimotor Stimulation on Oral Feeding
NCT06700135
Baby Brain Recovery Study
NCT05013736
Study of Bedside EEG to Evaluate Brain Injury in Premature Newborns
NCT00516334
Brain Activity During Birth for Prediction of Newborns at Risk for Brain Injury
NCT02445417
Primebrain Stimulation
NCT02159534
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This randomized controlled trial will enroll 120 term and near-term neonates with a history of asphyxia to 1-year of a standard follow-up program (provided by the Los Angeles Regional Centers) or a home-based intervention program (Utah State University's Developmental Curriculum and Monitoring System, CAMS). The experimental intervention will include individualized cognitive/neuromotor stimulation given by the child's parents under the guidance of public health nurses. Following the intervention, measures will be used to determine functional capacity (Bayley II scale and neurologic examination), behavioral outcomes (HOME and NCAST by developmental specialists), and maternal outcomes (including parent-infant interaction and perceived stress). Infants will be assessed after the 1-year intervention by psychologists and physicians masked to the intervention. Functional MRI brain studies will be conducted at discharge and 18 months of age at UCLA to assess qualitative and quantitative sensorimotor representation. Secondary outcomes include care stress and social support as reported by parents, and demographics and medical factors obtained from the hospital records.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Infant stimulation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Gestation age (GA) at birth \>= 28 weeks
* Discharged to home care with parent or other guardian who has legal authority to give informed consent
* Greater than 10th percentile for GA at birth using the scales according to Lubchenco, Hansman, and Boyd from Pediatrics 1966 volume 37 and Battaglia and Lubchenco in the Journal of Pediatrics 1967 volume 71
* Jewelry in pierced body parts can be removed
* Mothers \> 17 years old
* Recruited within 60 days of EDC (estimated date of conception)
Two or more of the following must be met:
* Intrapartum distress as determined by placental abruption, thick meconium staining of amniotic fluid, sustained fetal bradycardia of heart rate \< 100 beats/min, or late or absent heart rate variability
* Profound metabolic or mixed academia as determined by umbilical artery pH \< 7.0, base deficit of \> 10 mEq/L or pH \< 7.1 and base excess greater than 14 mmol/L within 72 hours of birth, Apgar score \< 5 at 5 minutes or beyond, or need for positive pressure ventilation resuscitation for \> 1 min after birth
* Neonatal neurological manifestations such as seizures during hospital stay, lethargy, hypotonia or hypertonia, stupor, flaccidity, or decerebration
* Multiple organ system dysfunction
* Abnormal EEG, CT scan, or MRI consistent with hypoxic or ischemic brain insult
Exclusion Criteria
* Intrauterine growth retardation (IUGR)
* Infants requiring extracorporeal membrane oxygenation (ECMO) in the neonatal period
* Hearing or visual impairment
* Congenital cyanotic heart disease with cyanosis and requiring PGE infusion. Children with minimum cardiac structural anomalies (e.g., PDA or VSD or peripheral pulmonary stenosis) will not be excluded from the study.
* Congenital abnormalities of the central nervous system such as congenital hydrocephalus
* Grade IV intraventicular hemorrhage requiring ventriculo-peritoneal shunt (VP shunt)
* Trisomy 13, 18, or 21, or Fragile X
* Metabolic encephalopathy from inborn errors of metabolism (e.g. PKU, OTC)
* Metal or wire mesh implants, pacemaker implants, cochlear implants, orthopedic surgical wires or implants
* Status epilepticus
* Ventilator dependent at discharge
* Infectious meningitis
* Encephalitis with radiological evidence of severe cortical or severe hemispheric destruction
* Silastic catheters, broviacs, or Hickman port home TPA
* Infants who may not be available for the duration of the study
* Any infant who in the opinion of investigator has no potential to benefit from the intervention (e.g., children with prenatal herpes meningitis, severe cortical destruction, mother does not follow up with the intervention or with the follow-up appointments)
1 Month
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Meena Garg, MD
Role: PRINCIPAL_INVESTIGATOR
University of California at Los Angeles
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California at Los Angeles
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NICHD-0115
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.